What we stand for: Takeki Uehara

As a " Drug-discovery- oriented pharmaceutical company," SHIONOGI has continued its efforts to create good drugs in terms of both efficacy and safety, and to increase those probability of success. In recent years, we have been promoting global development while maintaining an in-house drug discovery ratio of over 70%. While the in-house drug discovery ratio of most pharmaceutical companies is said to be 20-30%, I am proud that SHIONOGI maintains a high level of drug discovery capability and is able to deliver medicines from Japan to patients around the world.

Also, thankfully, I feel that society recognizes SHIONOGI as an "indispensable company." For example, SHIONOGI has long focused on the area of infectious diseases, and through the development of vaccines and therapeutics against COVID-19, we have received more encouragement and expectations for SHIONOGI than ever before.

To embody the company policy of SHIONOGI, we have a strong underlying desire to "efficiently create the best possible products to protect the health and wellbeing of the people and speedily deliver them to the people. " In order to achieve this goal, it is necessary to further improve the advanced technology and expertise we have cultivated as a "Drug-discovery- oriented pharmaceutical company" and raise it to the level that can only be achieved by SHIONOGI.

SHIONOGI's Drug Development and Regulatory Science Division has diverse human resources and has the flexibility to build a team while recognizing each person's individuality. We want to be a vibrant and attractive organization where each individual is keenly aware of the "desire" mentioned above and where individual diversity can be fully utilized.

Based on the human resources development policy that " people are the source of competitiveness," SHIONOGI aims to develop " Be the best you can be to take on new challenges." We will proactively provide employees with challenging opportunities that lead to their growth. We would also like to expand our network both inside and outside the company, create more opportunities to access information from various fields, and use the gained insights to improve the performance of individuals and organizations.

In addition, to meet the diverse needs of society, it is important to clearly envision the future image that the development product should aim for. To this end, we will communicate more actively not only with members in Japan but also with overseas and strengthen the structure for scientific discussions at the global level.

We will continue to embody the company policy of SHIONOGI and work as one to contribute to society as a company that "shapes the future of healthcare" through the development of " the best possible products to protect the health and wellbeing of the people.”

Drug Development and Regulatory Science Division

Senior Vice President, Dr. Takeki Uehara

July 1, 2022